Hepion Pharmaceuticals, Inc. HEPA · Stock Open Hepion Pharmaceuticals, Inc. in new tab
Hepion Pharmaceuticals, Inc. Analysis (HEPA)
Is Hepion Pharmaceuticals, Inc. a good investment? Hepion Pharmaceuticals, Inc. (HEPA) is currently trading at 0.0790 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.06. This relatively low multiple may signal that Hepion Pharmaceuticals, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Hepion Pharmaceuticals, Inc. is expected to release its next earnings report on Oct. 14, 2026. The market consensus estimate for Forward EPS is -11.43.
Investor FAQ
Does Hepion Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Hepion Pharmaceuticals, Inc.?
Hepion Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Oct. 14, 2026. The company currently has a trailing EPS of -0.03.
Company Profile
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.
| Split Date | Split Ratio to 1 |
|---|---|
| May 29, 2018 | Needs review |
| June 3, 2019 | 1:100 |
| May 11, 2023 | 1:20 |
| March 18, 2025 | 1:50 |
Community Discussion